Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 25.7% in July

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 5,870,000 shares, an increase of 25.7% from the June 30th total of 4,670,000 shares. Based on an average daily volume of 430,600 shares, the days-to-cover ratio is currently 13.6 days.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in Capricor Therapeutics in the first quarter worth about $40,000. Jump Financial LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $258,000. Bank of New York Mellon Corp lifted its position in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 1.4 %

Shares of CAPR stock traded down $0.06 during trading hours on Friday, reaching $4.37. 276,093 shares of the stock were exchanged, compared to its average volume of 541,852. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $8.22. The company’s 50-day moving average price is $5.11 and its 200-day moving average price is $5.13. The firm has a market capitalization of $139.75 million, a price-to-earnings ratio of -5.02 and a beta of 4.00.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, May 13th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.20). The company had revenue of $4.91 million for the quarter, compared to analysts’ expectations of $10.00 million. Capricor Therapeutics had a negative net margin of 89.72% and a negative return on equity of 231.68%. On average, sell-side analysts expect that Capricor Therapeutics will post -1.04 EPS for the current year.

Analysts Set New Price Targets

CAPR has been the topic of a number of recent analyst reports. StockNews.com cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, July 2nd. LADENBURG THALM/SH SH boosted their target price on Capricor Therapeutics from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, May 14th. Finally, Oppenheimer initiated coverage on shares of Capricor Therapeutics in a research note on Friday, May 17th. They set an “outperform” rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.75.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.